An AstraZeneca Plc executive said the British drugmaker would consider not submitting the company’s COVID-19 vaccine for approval in the United States if the regulatory process takes too long, the Financial Times reported on March 17.
U.S. Bankruptcy Court Judge Michael Kaplan ruled that Johnson & Johnson be allowed to continue with the company’s controversial spinoff strategy to settle with people who filed lawsuits claiming that J&J’s talc-based baby powder causes cancer.
Over the past six months, the Nasdaq Biotechnology Index has declined more than 20%. Some of the falling prices appear to be due to some investors losing interest in many companies that soared into favor during the COVID-19 pandemic. And these companies that have seen declining investor interest are now struggling to raise finances, according to BioSpace
The head of drugmaker Moderna said COVID-19 vaccines are unlikely to be as effective against the Omicron variant of the coronavirus as they have been previously, sparking fresh worry in financial markets about the trajectory of the pandemic.
With companies like GlaxoSmithKline and bluebird bio moving closer to splitting their businesses into multiple entities, Novartis is reviewing the Swiss drugmaker’s Sandoz division to determine the best moves going forward to maximize value for shareholders.
Top U.S. infectious disease expert Dr. Anthony Fauci called on China to release the medical records of nine people whose ailments might provide vital clues into whether Covid-19 first emerged as the result of a lab leak, the Financial Times reported on June 3.
The Covid-19 vaccine of AstraZeneca Plc and Oxford University works well as a third booster dose, stepping up antibodies to the coronavirus spike protein among participants in a study, the Financial Times said on May 19.
A panel of outside advisers to the U.S. Food and Drug Administration overwhelmingly endorsed emergency use of Moderna Inc.’s coronavirus vaccine, virtually assuring a second option for protecting against Covid-19 for a pandemic-ravaged nation.
An AstraZeneca executive said he felt encouraged by “incredibly promising” large-scale Covid-19 vaccine trial results unveiled by New York-based Pfizer and the company’s German partner BioNTech.
Moderna Inc. Chief Executive Officer Stéphane Bancel expects interim results from the company’s Covid-19 vaccine trial in November and that the U.S government could give an emergency use nod in December, the Wall Street Journal reported.
